<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291264</url>
  </required_header>
  <id_info>
    <org_study_id>10-04134</org_study_id>
    <nct_id>NCT01291264</nct_id>
  </id_info>
  <brief_title>Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] &amp; Neisseria Gonorrhoeae [NG] in Men Who Have Sex With Men [MSM]</brief_title>
  <official_title>Evaluation of Abbott RealTime CT/NG for the Detection of Chlamydia Trachomatis [CT] &amp; Neisseria Gonorrhoeae [NG] From the Pharynx, Rectum &amp; Urethra of Men Who Have Sex With Men [MSM]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Molecular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Julius Schachter, PhD, (Department of Laboratory Medicine, University of California, San
      Francisco) and Susan S. Philip, MD MPH (Department of Medicine, University of California, San
      Francisco) are conducting a study to evaluate the Abbott RealTime CT/NG polymerase chain
      reaction [PCR] assay (which is a nucleic acid amplification test [NAAT]) for detecting two
      sexually transmitted bacteria, Chlamydia trachomatis [CT] and Neisseria gonorrhoeae [NG],
      using urine samples and swabs from the throat and rectum of men who have sex with men [MSM].
      Using this test on these swabs is experimental because it has not been approved by the Food &amp;
      Drug Administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For each subject enrolled in the study, the following clinical data information will be
      obtained: 1) reason for exam, 2) subject's signs and symptoms and 3) clinical assessment.

      For each subject enrolled in the study, two clinician-collected pharyngeal swabs, two
      clinician-collected rectal swabs, and a first catch urine specimen (approximately 25 ml) will
      be obtained. The collection order of the clinician-collected swabs will be randomized.

      Two pharyngeal swabs will be tested at the research laboratory using: 1) APTIMA COMBO 2®
      [AC2](Gen-Probe Inc, San Diego, CA); and 2) Abbott RealTime CT/NG [RealTime](Abbott
      Molecular, Des Plains, IL). Two rectal swabs will be tested at the research laboratory using:
      1) AC2; and 2) RealTime.

      A first-catch urine [FCU] specimen will be split out at San Francisco Department of Public
      Health laboratory and sent to the Chlamydia Research Laboratory for analysis using: 1)AC2;
      and 2) RealTime.

      All NAAT specimens are collected in the manufacturer's recommended NAAT transport medium.
      After specimen processing, samples will be frozen at -70ºC for discrepant analysis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Abbott Molecular stopped funding of study
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Subject's Infected-status as Determined by the Nucleic Acid Amplification Assays Performed.</measure>
    <time_frame>1 day - (At clinic visit)</time_frame>
    <description>This is a single-point prevalence assessment done when subjects present at the STD clinic for routine STD screening. Subjects are not followed beyond the clinic visit.</description>
  </primary_outcome>
  <enrollment type="Actual">260</enrollment>
  <condition>Chlamydia Infection</condition>
  <condition>Gonococcal Infection</condition>
  <condition>Sexually Transmitted Diseases</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      clinician-collected rectal and pharyngeal swabs along with FCUs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men who have sex with men (MSM) voluntarily presenting at the City STD clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject must be MSM. Subjects must provide verbal consent, must be able to submit
             all required specimens and must not have urinated within 1 hr prior to providing a
             study urine specimen.

        Exclusion Criteria:

          -  Subjects are excluded if they do not have sex with men, refuse to give verbal consent
             or refuse to allow such consent to be documented in their chart, are unable to provide
             all required specimens and minimum specimen volume, have been on antibiotic therapy
             within the last 21 days, have urinated within 1 hr prior to submitting study
             specimens, and have already been evaluated as part of this trial. Subjects will be
             excluded if specimens are mishandled or inappropriately stored.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julius Schachter, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SF City Clinic</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Johnson RE, Newhall WJ, Papp JR, Knapp JS, Black CM, Gift TL, Steece R, Markowitz LE, Devine OJ, Walsh CM, Wang S, Gunter DC, Irwin KL, DeLisle S, Berman SM. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections--2002. MMWR Recomm Rep. 2002 Oct 18;51(RR-15):1-38; quiz CE1-4.</citation>
    <PMID>12418541</PMID>
  </reference>
  <reference>
    <citation>Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010 Dec 17;59(RR-12):1-110. Erratum in: MMWR Recomm Rep. 2011 Jan 14;60(1):18. Dosage error in article text.</citation>
    <PMID>21160459</PMID>
  </reference>
  <reference>
    <citation>Page-Shafer K, Graves A, Kent C, Balls JE, Zapitz VM, Klausner JD. Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhea in men who have sex with men. Clin Infect Dis. 2002 Jan 15;34(2):173-6. Epub 2001 Dec 7.</citation>
    <PMID>11740704</PMID>
  </reference>
  <reference>
    <citation>Van Der Pol B, Ferrero DV, Buck-Barrington L, Hook E 3rd, Lenderman C, Quinn T, Gaydos CA, Lovchik J, Schachter J, Moncada J, Hall G, Tuohy MJ, Jones RB. Multicenter evaluation of the BDProbeTec ET System for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs, and male urethral swabs. J Clin Microbiol. 2001 Mar;39(3):1008-16.</citation>
    <PMID>11230419</PMID>
  </reference>
  <reference>
    <citation>Ciemins EL, Flood J, Kent CK, Shaw H, Rowniak S, Moncada J, Klausner JD, Schachter J. Reexamining the prevalence of Chlamydia trachomatis infection among gay men with urethritis: implications for STD policy and HIV prevention activities. Sex Transm Dis. 2000 May;27(5):249-51.</citation>
    <PMID>10821595</PMID>
  </reference>
  <reference>
    <citation>Rompalo AM, Price CB, Roberts PL, Stamm WE. Potential value of rectal-screening cultures for Chlamydia trachomatis in homosexual men. J Infect Dis. 1986 May;153(5):888-92.</citation>
    <PMID>3084665</PMID>
  </reference>
  <reference>
    <citation>Chernesky MA, Martin DH, Hook EW, Willis D, Jordan J, Wang S, Lane JR, Fuller D, Schachter J. Ability of new APTIMA CT and APTIMA GC assays to detect Chlamydia trachomatis and Neisseria gonorrhoeae in male urine and urethral swabs. J Clin Microbiol. 2005 Jan;43(1):127-31.</citation>
    <PMID>15634960</PMID>
  </reference>
  <reference>
    <citation>Schachter J, Moncada J, Liska S, Shayevich C, Klausner JD. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis. 2008 Jul;35(7):637-42. doi: 10.1097/OLQ.0b013e31817bdd7e.</citation>
    <PMID>18520976</PMID>
  </reference>
  <reference>
    <citation>Kent CK, Chaw JK, Wong W, Liska S, Gibson S, Hubbard G, Klausner JD. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis. 2005 Jul 1;41(1):67-74. Epub 2005 May 26.</citation>
    <PMID>15937765</PMID>
  </reference>
  <reference>
    <citation>Laboratory Diagnostic Testing for Chlamydia trachomatis and Neisseria gonorrhoeae. American Public Health Laboratories/Center for Disease Control &amp; Prevention Panel Summary Reports. January 2009. Internet. Accessed 8 November 2010. http://www.aphl.org/aphlprograms/infectious/std/Documents/CTGCLabGuidelinesMeetingReport.pdf</citation>
  </reference>
  <reference>
    <citation>Moncada J, Schachter J, Liska S, Shayevich C, Klausner JD. Evaluation of self-collected glans and rectal swabs from men who have sex with men for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of nucleic acid amplification tests. J Clin Microbiol. 2009 Jun;47(6):1657-62. doi: 10.1128/JCM.02269-08. Epub 2009 Apr 15.</citation>
    <PMID>19369445</PMID>
  </reference>
  <reference>
    <citation>Gaydos CA, Cartwright CP, Colaninno P, Welsch J, Holden J, Ho SY, Webb EM, Anderson C, Bertuzis R, Zhang L, Miller T, Leckie G, Abravaya K, Robinson J. Performance of the Abbott RealTime CT/NG for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol. 2010 Sep;48(9):3236-43. doi: 10.1128/JCM.01019-10. Epub 2010 Jul 28.</citation>
    <PMID>20668135</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <results_first_submitted>January 21, 2014</results_first_submitted>
  <results_first_submitted_qc>January 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2014</results_first_posted>
  <last_update_submitted>January 21, 2014</last_update_submitted>
  <last_update_submitted_qc>January 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chlamydia trachomatis</keyword>
  <keyword>Neisseria gonorrhoeae</keyword>
  <keyword>Sexually Transmitted Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Chlamydia Infections</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
    <mesh_term>Gonorrhea</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment dates were 06/06/12 to 09/19/12. Study was done at the San Francisco City STD Clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Men Who Have Sex With Men</title>
          <description>The study population consisted of asymptomatic and symptomatic MSM that could provide approximately 25 ml of first catch urine (FCU), and two clinician-collected pharyngeal and rectal swabs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Men who have sex with men</population>
      <group_list>
        <group group_id="B1">
          <title>Men Who Have Sex With Men</title>
          <description>The study population consisted of asymptomatic and symptomatic MSM that could provide approximately 25 ml of first catch urine (FCU), and two clinician-collected pharyngeal and rectal swabs.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="260"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject's Infected-status as Determined by the Nucleic Acid Amplification Assays Performed.</title>
        <description>This is a single-point prevalence assessment done when subjects present at the STD clinic for routine STD screening. Subjects are not followed beyond the clinic visit.</description>
        <time_frame>1 day - (At clinic visit)</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Men Who Have Sex With Men</title>
            <description>The study population consisted of asymptomatic and symptomatic MSM that could provide approximately 25 ml of first catch urine (FCU), and two clinician-collected pharyngeal and rectal swabs.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Infected-status as Determined by the Nucleic Acid Amplification Assays Performed.</title>
          <description>This is a single-point prevalence assessment done when subjects present at the STD clinic for routine STD screening. Subjects are not followed beyond the clinic visit.</description>
          <population>per protocol</population>
          <units>Positive test result</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oropharynx tested by RealTime for NG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oropharynx tested by AC2 for NG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum tested by RealTime for NG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum tested by AC2 for NG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FCU tested by RealTime for NG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FCU tested by AC2 for NG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oropharynx tested by RealTime for CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oropharynx tested by AC2 for CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum tested by RealTime for CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectum tested by AC2 for CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FCU tested by RealTime for CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FCU tested by AC2 for CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Men Who Have Sex With Men</title>
          <description>The study population consisted of asymptomatic and symptomatic MSM that could provide approximately 25 ml of first catch urine (FCU), and two clinician-collected pharyngeal and rectal swabs.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our limitations are small number of subjects enrolled due to early termination of the study and we had no pharyngeal CT infections.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Julius Schachter, Professor of Laboratory Medicine</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415 824 5115</phone>
      <email>julius.schachter@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

